Author Archives: admin001

BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

PHILADELPHIA and VANCOUVER, British Columbia, March 10, 2026 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

PHILADELPHIA and VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Independent DSMB has identified no safety concerns, and recommends continuation of BriaCell’s pivotal Phase 3 ...

BriaCell Patients’ Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

Images below confirm clinical responses seen in patients with metastatic orbital (eye), temporal (brain), liver, ...

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

9 of 25 BriaCell patients treated since 2022 remain alive >18-47 months post enrollment, markedly ...

BriaCell Therapeutics Announces Pricing of $15 million Public Offering

PHILADELPHIA and VANCOUVER, British Columbia, July 15, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer

PHILADELPHIA and VANCOUVER, British Columbia, July 15, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified

Phase 3 clinical data shows potential predictive biomarkers for treatment response, first identified in Phase ...

BriaCell Therapeutics Announces Closing of $13.8 million Public Offering

PHILADELPHIA and VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...